跳至主要内容
临床试验/EUCTR2021-006781-21-FR
EUCTR2021-006781-21-FR进行中(未招募)1 期

ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials

ovartis Pharma AG0 个研究点目标入组 260 人开始时间: 2022年8月18日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
260

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Participants eligible for inclusion in this study must meet all of the following criteria:
  • 1. Received OAV101 IT or OAV101 IV in a Phase I to IIIb clinical trial sponsored by AveXis, Novartis or Novartis Gene Therapies.
  • 2. Patient/Parent/legal guardian willing and able to complete the informed consent process and comply with study procedures.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 260
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Score yes” on item 4 or item 5 of the suicidal ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or yes” on any item of the suicidal behavior section, except for the Non-Suicidal Self-Injurious Behavior” (item also included in the suicidal behavior section) if this behavior occurred in the past 2 years.

研究者

相似试验